acetazolamide has been researched along with Calcinosis in 16 studies
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)
Calcinosis: Pathologic deposition of calcium salts in tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe a patient with tumoral calcinosis, in which acetazolamide (ACZ) was, for the first time, tested for its therapeutic efficacy." | 7.69 | Successful treatment of hyperphosphatemic tumoral calcinosis with long-term acetazolamide. ( Chihara, K; Fujita, T; Fukase, M; Imai, Y; Sugimoto, T; Yamaguchi, T, 1995) |
| "The effect of the carbonic anhydrase inhibitor acetazolamide on intraocular pressure was studied in two patients with carbonic anhydrase II deficiency and in six control subjects." | 7.67 | Failure of acetazolamide to decrease intraocular pressure in patients with carbonic anhydrase II deficiency. ( Dodgson, SJ; Krupin, T; Sly, WS; Whyte, MP, 1985) |
| "Hyperphosphatemic familial tumoral calcinosis (HFTC) is a rare autosomal recessive disorder." | 5.72 | The Successful Treatment of Deep Soft-tissue Calcifications with Topical Sodium Thiosulphate and Acetazolamide in a Boy with Hyperphosphatemic Familial Tumoral Calcinosis due to a Novel Mutation in ( Döneray, H; Gürbüz, K; Özden, A, 2022) |
| "Familial hyperphosphatemic tumoral calcinosis is a rare disorder characterized by hyperphosphatemia with recurrent ectopic periarticular calcifications, in addition to other visceral and vascular manifestations, without any inflammatory or neoplastic disorder." | 5.62 | Familial hyperphosphatemic tumoral calcinosis in an unusual and usual sites and dramatic improvement with the treatment of acetazolamide, sevelamer and topical sodium thiosulfate. ( Aktasoglu, E; Emecen Sanli, M; Ezgu, F; Inci, A; Kilic, A; Okur, I; Tumer, L, 2021) |
| "Hyperphosphatemic familial tumoral calcinosis (HFTC) is characterized by enhanced renal phosphate absorption, hyperphosphatemia, and tumor-like extraosseous calcifications due to inactivating mutations in FGF23 or associated proteins." | 5.40 | Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms. ( Finer, G; Langman, CB; Price, HE; Shore, RM; White, KE, 2014) |
| "Hyperphosphatemic familial tumoral calcinosis (HFTC) is an uncommon disease characterized by periarticular calcifications produced by the deposition of amorphous extraosseous calcifications of hydroxyapatite." | 5.35 | Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer. ( Lammoglia, JJ; Mericq, V, 2009) |
| "We studied two related patients who had tumoral calcinosis and hyperphosphatemia and two normal controls to determine their renal tubular response to parathyroid hormone (PTH) and acetazolamide (ACZ)." | 5.26 | Phosphorus excretion in tumoral calcinosis: response to parathyroid hormone and acetazolamide. ( Bill, NJ; DeLuca, HF; Dousa, TP; Knox, FG; Lufkin, EG; Smith, LH; Wilson, DM, 1980) |
| "We describe a patient with tumoral calcinosis, in which acetazolamide (ACZ) was, for the first time, tested for its therapeutic efficacy." | 3.69 | Successful treatment of hyperphosphatemic tumoral calcinosis with long-term acetazolamide. ( Chihara, K; Fujita, T; Fukase, M; Imai, Y; Sugimoto, T; Yamaguchi, T, 1995) |
| "The effect of the carbonic anhydrase inhibitor acetazolamide on intraocular pressure was studied in two patients with carbonic anhydrase II deficiency and in six control subjects." | 3.67 | Failure of acetazolamide to decrease intraocular pressure in patients with carbonic anhydrase II deficiency. ( Dodgson, SJ; Krupin, T; Sly, WS; Whyte, MP, 1985) |
| "Hyperphosphatemic familial tumoral calcinosis (HFTC) is a rare autosomal recessive disorder." | 1.72 | The Successful Treatment of Deep Soft-tissue Calcifications with Topical Sodium Thiosulphate and Acetazolamide in a Boy with Hyperphosphatemic Familial Tumoral Calcinosis due to a Novel Mutation in ( Döneray, H; Gürbüz, K; Özden, A, 2022) |
| "Familial hyperphosphatemic tumoral calcinosis is a rare disorder characterized by hyperphosphatemia with recurrent ectopic periarticular calcifications, in addition to other visceral and vascular manifestations, without any inflammatory or neoplastic disorder." | 1.62 | Familial hyperphosphatemic tumoral calcinosis in an unusual and usual sites and dramatic improvement with the treatment of acetazolamide, sevelamer and topical sodium thiosulfate. ( Aktasoglu, E; Emecen Sanli, M; Ezgu, F; Inci, A; Kilic, A; Okur, I; Tumer, L, 2021) |
| "Hyperphosphatemic familial tumoral calcinosis (HFTC) is characterized by enhanced renal phosphate absorption, hyperphosphatemia, and tumor-like extraosseous calcifications due to inactivating mutations in FGF23 or associated proteins." | 1.40 | Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms. ( Finer, G; Langman, CB; Price, HE; Shore, RM; White, KE, 2014) |
| "Tumoral calcinosis is a rare condition characterised by progressive, ectopic, periarticular deposits of calcium." | 1.40 | Familial tumoral calcinosis. ( Alkhatib, A; Burton, LE; Carachi, R, 2014) |
| "Treatment with niacinamide and acetazolamide decreased TmP/GFR and serum phosphate, which was paralleled by a decrease in serum C-terminus FGF23." | 1.35 | A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features. ( Brahim, J; Collins, MT; Dumitrescu, CE; Farrow, EG; Hart, TC; Kelly, MH; Khosravi, A; Murphey, MD; Nathan, MH; White, KE, 2009) |
| "Hyperphosphatemic familial tumoral calcinosis (HFTC) is an uncommon disease characterized by periarticular calcifications produced by the deposition of amorphous extraosseous calcifications of hydroxyapatite." | 1.35 | Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer. ( Lammoglia, JJ; Mericq, V, 2009) |
| "We studied two related patients who had tumoral calcinosis and hyperphosphatemia and two normal controls to determine their renal tubular response to parathyroid hormone (PTH) and acetazolamide (ACZ)." | 1.26 | Phosphorus excretion in tumoral calcinosis: response to parathyroid hormone and acetazolamide. ( Bill, NJ; DeLuca, HF; Dousa, TP; Knox, FG; Lufkin, EG; Smith, LH; Wilson, DM, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (37.50) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Döneray, H | 1 |
| Özden, A | 1 |
| Gürbüz, K | 1 |
| Emecen Sanli, M | 1 |
| Kilic, A | 1 |
| Aktasoglu, E | 1 |
| Inci, A | 1 |
| Okur, I | 1 |
| Ezgu, F | 1 |
| Tumer, L | 1 |
| Finer, G | 1 |
| Price, HE | 1 |
| Shore, RM | 1 |
| White, KE | 2 |
| Langman, CB | 1 |
| Alkhatib, A | 1 |
| Burton, LE | 1 |
| Carachi, R | 1 |
| Landini-Enríquez, V | 1 |
| Escamilla, MA | 1 |
| Soto-Vega, E | 1 |
| Chamizo-Aguilar, K | 1 |
| Dumitrescu, CE | 1 |
| Kelly, MH | 1 |
| Khosravi, A | 1 |
| Hart, TC | 1 |
| Brahim, J | 1 |
| Farrow, EG | 1 |
| Nathan, MH | 1 |
| Murphey, MD | 1 |
| Collins, MT | 1 |
| Lammoglia, JJ | 1 |
| Mericq, V | 1 |
| HARRISON, HE | 1 |
| HARRISON, HC | 1 |
| WERNER, E | 1 |
| Otukesh, H | 1 |
| Hoseini, R | 1 |
| Chalian, H | 1 |
| Chalian, M | 1 |
| Safarzadeh, AE | 1 |
| Shakiba, M | 1 |
| Poorian, A | 1 |
| Bard, H | 1 |
| Kuntz, D | 1 |
| Molle, D | 1 |
| Witvoet, J | 1 |
| Ryckewaert, A | 1 |
| Lufkin, EG | 1 |
| Wilson, DM | 1 |
| Smith, LH | 1 |
| Bill, NJ | 1 |
| DeLuca, HF | 1 |
| Dousa, TP | 1 |
| Knox, FG | 1 |
| Yamaguchi, T | 1 |
| Sugimoto, T | 1 |
| Imai, Y | 1 |
| Fukase, M | 1 |
| Fujita, T | 1 |
| Chihara, K | 1 |
| Doita, M | 1 |
| Terukina, M | 1 |
| Mizuno, K | 1 |
| Weisinger, JR | 1 |
| Mogollón, A | 1 |
| Lander, R | 1 |
| Bellorin-Font, E | 1 |
| Riera, R | 1 |
| Abadí, I | 1 |
| Paz-Martínez, V | 1 |
| Krupin, T | 1 |
| Sly, WS | 1 |
| Whyte, MP | 1 |
| Dodgson, SJ | 1 |
16 other studies available for acetazolamide and Calcinosis
| Article | Year |
|---|---|
The Successful Treatment of Deep Soft-tissue Calcifications with Topical Sodium Thiosulphate and Acetazolamide in a Boy with Hyperphosphatemic Familial Tumoral Calcinosis due to a Novel Mutation in
Topics: Acetazolamide; Calcinosis; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperosto | 2022 |
Familial hyperphosphatemic tumoral calcinosis in an unusual and usual sites and dramatic improvement with the treatment of acetazolamide, sevelamer and topical sodium thiosulfate.
Topics: Acetazolamide; Administration, Topical; Anticonvulsants; Antioxidants; Calcinosis; Chelating Agents; | 2021 |
Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms.
Topics: Acetazolamide; Acidosis; Black or African American; Calcinosis; Carbonic Anhydrase Inhibitors; Chela | 2014 |
Familial tumoral calcinosis.
Topics: Acetazolamide; Calcinosis; Calcium Phosphates; Carbonic Anhydrase Inhibitors; Female; Fibroblast Gro | 2014 |
Response to acetazolamide in a patient with tumoral calcinosis.
Topics: Acetazolamide; Adolescent; Buttocks; Calcinosis; Calcium Phosphates; Carbonic Anhydrase Inhibitors; | 2015 |
A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.
Topics: Acetazolamide; Adult; Calcinosis; Child; Diuretics; Female; Fibroblast Growth Factor-23; Fibroblast | 2009 |
Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer.
Topics: Acetazolamide; Acidosis, Renal Tubular; Calcinosis; Chelating Agents; Child, Preschool; Diuretics; D | 2009 |
Inhibition of urine citrate excretion and the production of renal calcinosis in the rat by acetazoleamide (diamox) administration.
Topics: Acetazolamide; Animals; Calcinosis; Citrates; Citric Acid; Diuretics; Hydro-Lyases; Kidney Diseases; | 1955 |
[CLINICAL CONTRIBUTION ON THE CALCIUM-LOWERING EFFECT OF DIAMOX IN DERMATOMYOSITIS WITH INTERSTITIAL CALCINOSIS AND HYPERCALCEMIA].
Topics: Acetazolamide; Calcinosis; Calcium, Dietary; Child; Dermatomyositis; Drug Therapy; Humans; Hypercalc | 1964 |
Hyperostosis with hyperphosphatemia and tumoral calcinosis: a case report.
Topics: Acetazolamide; Calcinosis; Calcium; Calcium Carbonate; Carbonic Anhydrase Inhibitors; Chelating Agen | 2007 |
[Phosphorus metabolism in a case of tumoral calcinosis].
Topics: Acetazolamide; Adult; Black People; Calcinosis; Calcium; Humans; Male; Parathyroid Hormone; Phosphor | 1984 |
Phosphorus excretion in tumoral calcinosis: response to parathyroid hormone and acetazolamide.
Topics: Acetazolamide; Adolescent; Blood Chemical Analysis; Bone and Bones; Calcinosis; Calcium; Female; Hum | 1980 |
Successful treatment of hyperphosphatemic tumoral calcinosis with long-term acetazolamide.
Topics: Acetazolamide; Administration, Oral; Adult; Aluminum Hydroxide; Calcinosis; Drug Therapy, Combinatio | 1995 |
[A case report of systemic calcinosis associated with rheumatoid arthritis].
Topics: Acetazolamide; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Calcinosis; Carbonic Anhydrase | 1996 |
Massive cerebral calcifications associated with increased renal phosphate reabsorption.
Topics: Absorption; Acetazolamide; Adolescent; Brain Diseases; Calcinosis; Calcium; Cerebral Cortex; Edetic | 1986 |
Failure of acetazolamide to decrease intraocular pressure in patients with carbonic anhydrase II deficiency.
Topics: Acetazolamide; Acidosis, Renal Tubular; Adult; Brain Diseases; Calcinosis; Carbonic Anhydrases; Fema | 1985 |